RT Journal Article SR Electronic T1 Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.21.21260391 DO 10.1101/2021.07.21.21260391 A1 Athena Akrami A1 Gina Assaf A1 Hannah Davis A1 Karen Harris A1 Akiko Iwasaki A1 Harlan Krumholz A1 Daisy Massey A1 Lisa McCorkell A1 Aaron M Ring A1 Wade L Schulz A1 Hannah Wei YR 2021 UL http://medrxiv.org/content/early/2021/07/24/2021.07.21.21260391.abstract AB As more people are vaccinated against SARS-CoV-2, many of those already infected are still suffering from Post-Acute Sequelae (PASC). Although there is no current treatment for PASC, reports from patients that the vaccine itself improves, and in some reports, worsens, PASC symptoms may lead to a deeper understanding of the causes of PASC symptoms and viable treatments. As such, we are conducting a study that measures the changes in PASC symptoms after vaccination. We are collecting baseline self-report and biospecimens for immune assays and then are following up with participants to collect the same data at 2-weeks, 6-weeks, and 12-weeks post-vaccination (first dose). Immune assays using blood specimens will include B-cell, T-cell, and myeloid cell panels; evaluation of T-cell responsiveness to SARS-CoV-2 peptides and antigen specific response; autoantibody screening (of IgG, IgM, and IgA antibodies that attack human proteins); and TCR sequencing and antigen mapping of CD8+ T-cells. Mucosal immunity will be measured using saliva specimens. The study aims to provide answers for people with PASC, especially regarding the causes of their symptoms and how the vaccine may affect them, and clues for PASC treatment.Competing Interest StatementAaron Ring is an inventor of the REAP technology and founder of Seranova Bio, a company that will commercialize this technology. Akiko Iwasaki has served as a consultant to Adaptive Biotechnologies for a one-day meeting.Clinical TrialNCT04895189Funding StatementNo external funding has been received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University Institutional Review Board, IRB 2000030423 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis protocol and surveys are available to any researcher who requests them and can be found, in addition to MedRxiv, by emailing dorothy.massey{at}yale.edu.